Metabolomics and Proteomics in Chronic Obstructive Pulmonary Disease (COPD)

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Metabolism".

Deadline for manuscript submissions: 1 May 2024 | Viewed by 1389

Special Issue Editor

Prof. Dr. Joaquim Gea Guiral
E-Mail Website
Guest Editor
Hospital del Mar–IMIM, Universitat Pompeu Fabra, Barcelona, Spain
Interests: COPD; respiratory and muscle physiology; biomarkers

Special Issue Information

Dear Colleagues,

Chronic Obstructive Pulmonary Disease (COPD) is mainly characterized by chronic airflow obstruction but shows very heterogeneous clinical presentations (called phenotypes or treatable traits). These phenotypes are believed to correspond to partially differentiated biological mechanisms (endotypes). This constitutes a difficulty for the practice of a more personalized medicine since it is necessary to obtain specific clinical and/or biological markers. The latter is linked to the above-mentioned phenotypes, whose search can be performed by either following specific hypotheses using conventional techniques or by using a broader approach such as that of omic sciences. Metabolomics and proteomics stand out among these as it allows the identification and quantification of metabolites and peptides/proteins, respectively, with subsequent deduction of the biological processes where these molecules are involved. To date, many metabolomic and proteomic studies have been carried out aimed at defining those changes typical when considering COPD as a whole entity and the more specific ones that are characteristic of its different phenotypes. Most of these studies have been done on blood samples due to the easy obtention and potential future clinical applicability. Some studies have also been carried out on samples from the respiratory system, and even in urine. In general, the different authors agree on the relevance of the changes observed in the metabolism of peptides/proteins and some lipids (mainly fatty acids and phospholipids) in patients with COPD, with direct implications in the pathways linked to inflammation and oxidative stress, as well as protein catabolism and energy production. Regarding the main COPD phenotypes, it seems that patients with emphysema exhibit an overproduction of free radicals, with abnormalities in the citric acid cycle, protein catabolism and oxidative phosphorylation. In turn, patients who suffer frequent exacerbations show dysregulation of the phospholipid, purine, amino acid, and ATP-binding cassette carrier (ABC) metabolism, while those patients characterized by showing a high number of blood eosinophils mostly exhibit changes in the metabolism of eicosanoids and certain cytokines, as well as a strong energy consumption. Moreover, specific metabolic changes linked to the age or the sex of COPD patients have also been described. However, the profiles and models that have already been proposed are not clearly defined and most still lack validation. For this reason, more studies should be carried out to allow the translation of the metabolomic results to the clinical management of COPD patients.

In this Special Issue, we aim to include studies that cover cell biology and physiology, molecular biology, and biophysics of Chronic Obstructive Pulmonary Disease.

Prof. Dr. Joaquim Gea Guiral
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • COPD
  • phenotypes
  • metabolites
  • biomarkers
  • inflammation
  • energy production
  • protein catabolism
  • phospholipids
  • peptides

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


25 pages, 16017 KiB  
Systematic Review
Arginine, Transsulfuration, and Folic Acid Pathway Metabolomics in Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis
Cells 2023, 12(17), 2180; - 30 Aug 2023
Viewed by 1061
There is an increasing interest in biomarkers of nitric oxide dysregulation and oxidative stress to guide management and identify new therapeutic targets in patients with chronic obstructive pulmonary disease (COPD). We conducted a systematic review and meta-analysis of the association between circulating metabolites [...] Read more.
There is an increasing interest in biomarkers of nitric oxide dysregulation and oxidative stress to guide management and identify new therapeutic targets in patients with chronic obstructive pulmonary disease (COPD). We conducted a systematic review and meta-analysis of the association between circulating metabolites within the arginine (arginine, citrulline, ornithine, asymmetric, ADMA, and symmetric, SDMA dimethylarginine), transsulfuration (methionine, homocysteine, and cysteine) and folic acid (folic acid, vitamin B6, and vitamin B12) metabolic pathways and COPD. We searched electronic databases from inception to 30 June 2023 and assessed the risk of bias and the certainty of evidence. In 21 eligible studies, compared to healthy controls, patients with stable COPD had significantly lower methionine (standardized mean difference, SMD = −0.50, 95% CI −0.95 to −0.05, p = 0.029) and folic acid (SMD = −0.37, 95% CI −0.65 to −0.09, p = 0.009), and higher homocysteine (SMD = 0.78, 95% CI 0.48 to 1.07, p < 0.001) and cysteine concentrations (SMD = 0.34, 95% CI 0.02 to 0.66, p = 0.038). Additionally, COPD was associated with significantly higher ADMA (SMD = 1.27, 95% CI 0.08 to 2.46, p = 0.037), SDMA (SMD = 3.94, 95% CI 0.79 to 7.08, p = 0.014), and ornithine concentrations (SMD = 0.67, 95% CI 0.13 to 1.22, p = 0.015). In subgroup analysis, the SMD of homocysteine was significantly associated with the biological matrix assessed and the forced expiratory volume in the first second to forced vital capacity ratio, but not with age, study location, or analytical method used. Our study suggests that the presence of significant alterations in metabolites within the arginine, transsulfuration, and folic acid pathways can be useful for assessing nitric oxide dysregulation and oxidative stress and identifying novel treatment targets in COPD. (PROSPERO registration number: CRD42023448036.) Full article
Show Figures

Figure 1

Back to TopTop